Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Thumbnail

Former Aetna CEO cites ‘tension’ in CVS board changes

The former CEO of health insurer Aetna, which was acquired by CVS Health for $69 billion at the end of 2018, says he is being pushed off the board of the combined company.

 

Thumbnail

Trump admin’s Medicaid block grants met with industry backlash

Medicaid block grants, which have been framed as an “opportunity” for states to better control their Medicaid spending and gain flexibility, have been harshly criticized by healthcare groups.

Thumbnail

Will AI be a part of Trump’s State of the Union address?

President Trump is scheduled to deliver his State of the Union address on Tuesday, Feb. 4, at a time when most Americans have been focused on impeachment, the 2020 election and the coronavirus outbreak.

Thumbnail

Trump administration announces Medicaid block grants under new branding

The Trump administration has released its Medicaid block grant program under a new name that allows states to designate funding and put a cap on Medicaid spending. The program, dubbed Healthy Adults Opportunity, is an optional intervention initiative that fundamentally changes the way part of Medicaid is funded.

Thumbnail

CVS debuts insulin program with no out-of-pocket costs

CVS Health recently launched an insulin program for employers and health plan sponsors to offer diabetes medications with zero out-of-pocket costs for members. The program could help alleviate the rising costs of insulin for people managing diabetes.

Thumbnail

CMS expands coverage to genetic sequencing for cancer patients

CMS will now cover Next Generation Sequencing through FDA-approved or cleared lab diagnostic tests for patients with inherited ovarian or breast cancer.

Thumbnail

Pharma industry lobbying hit $29M in 2019

The pharmaceutical industry upped its lobbying efforts in 2019, with a record-high of $29 million spent lobbying Congress.

Thumbnail

Civica Rx, Blue Cross Blue Shield tackle high-cost generic medications with new subsidiary

Civica Rx and the Blue Cross Blue Shield Association and 18 of its health plans have teamed up to create a new subsidiary that will target low-cost generic drugs.

Around the web

The FTC alleges that pharmacy benefit managers have set up a system where they get rich, while patients are forced to pay rising insulin costs. The agency also called out drug manufacturers such as Eli Lilly, Sanofi and Novo Nordisk, saying their own actions have raised serious concerns.

In the post-COVID era, wages for permanent RNs are rising, and wages for travelers are decreasing. A new report tracked these trends and more. 

Two medical device companies have announced a transaction that could shake up the U.S. electrophysiology market. 

Trimed Popup
Trimed Popup